SPHINX31 (C007B-273107)

InformationSPHINX31 SPHINX31 is a SRPK1 inhibiror with an IC50 of 5.9 nM with highly selectivity for SRPK1 over SRPK2 (50-fold) and CLK1 (100-fold).TargetsSRPK1 (Cell-free assay) 5.9 nMIn vitroKinase assays showed that SPHINX31 is a type 1 kinase inhibitor (ATP competitive). SPHINX31 treatment results in inhibition of SRSF1 phosphorylation at 300 nM in PC3 prostate cancer cells. Metabolic stability in mouse liver microsomes shows that SPHINX31 had medium clearance with a T1/2 of 95.79 min. Inhibition of SRPK1 using SPHINX31 leads to cell cycle arrest and leukemic cell differentiation.In vivoSPHINX31 could penetrate into the eye. SPHINX31 exerts a dose dependent inhibition of choroidal neovascularisation in mouse model. SPHINX31 inhibits blood vessel growth and macrophage infiltration. SPHINX31 treatment prolongs survival of immunocompromised mice transplanted with MLL-rearranged AML cells.Cell Research(from reference)Cell lines：THP1 cells Concentrations：3/u2009µM Incubation Time：24 h. Specification: 10mM in DMSO Molecular Formula: C27H24F3N5O2 Molecular Weight: 507.51 PubChem CID: 91972002 Isomeric SMILES: C1CN(CCN1CC2=CC=CC=N2)C3=C(C=C(C=C3)C(F)(F)F)NC(=O)C4=CC=C(O4)C5=CC=NC=C5

UPC:

51111617

Condition:

New

Weight:

0.85 Ounces

HazmatClass:

No

Quantity:

1

Unit of Measurement:

EA

WeightUOM:

LB

MPN:

S422230-1ml

CAS:

1818389-84-2

Product Size:

1ml